Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience powered by Apple
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions powered by Apple

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/

Nota de prensa

Impacto sobre el mercado farmacéutico del borrador de la OPR del 3 de agosto de 2018

ago. 13, 2018

En IQVIA se ha elaborado un análisis del impacto que tendría en el mercado farmacéutico el borrador de la OPR del 3 de agosto de 2018 que se encuentra tramitando el Ministerio de Sanidad. 

A lo largo del análisis se destacan los siguiente puntos clave: 

La aplicación de la OPR en el mercado de reembolso genera una reducción anual un 50% mayor que la OPR de noviembre de 2017 y supone un impacto de 91M€ en el mercado farmacéutico de reembolso

Se toma como referencia el volumen de unidades vendido en los últimos doce meses (agosto 2017-julio 2018)

  • Previo a la aplicación de la OPR, la variación de precios ocurrida en los últimos doce meses genera una reducción de 120M€ en el valor del segmento de reembolso a PVL.
    • Dicha circunstancia afecta tanto al segmento del mercado de reembolso sujeto a la aplicación de la OPR, con 76M€…
    • Como al segmento de productos no sujetos a precio de referencia donde la bajada de precios en el último año supone una disminución de 45M€. 
  • Los nuevos precios de referencia se aplicarán en el momento en que entre en vigor la OPR y se calculan teniendo en cuenta los precios menores activos según el sistema de agrupaciones homogéneas, al hacerlo el valor anual del segmento de reembolso se reduce 91M€ que se suman a los 76M€ resultantes de la aplicación del ultimo precio:
    • Estos 91M€ suponen una variación de un -1,9% en el segmento de mercado sujeto a precio de referencia.
    • El 97% del impacto de la OPR se concentra en productos no genéricos.
    • Si a la OPR se añade el efecto del precio actual (variación de precios en los últimos doce meses), el segmento de marcas sujetas a precio de referencia disminuye su valor en un -5% (151M€).  El efecto negativo sobre el segmento de genéricos puede suponer una disminución por valor de 16M€.
  • En línea con 2017 el 53% del efecto conjunto precios menores + OPR corresponde a conjuntos homogéneos de nueva creación y dentro de ellos el 96% (125M€) afecta a productos no genéricos.
  • Hay 19 CH’s de nueva creación, pero solo en 5 de ellos la definición de un precio de referencia tiene un efecto real de reducción del valor y supone casi el 50% del impacto total de la aplicación de la OPR.

Haga clic aquí para ver el análisis completo

Contact Us